SCHEMBL1633057

SCHEMBL1633057

CC(=O)N1CCN(Cc2cncc(-c3cccc4cnc(Nc5ccc(S(N)(=O)=O)cc5)nc34)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.51
▸ MAPK10 P53779 2/20 0.44
▸ FGFR2 P21802 1/20 0.43
▸ CA12 O43570 2/20 0.42
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ TBK1 Q9UHD2 2/20 0.42
▸ JAK2 O60674 5/20 0.42
▸ TYK2 P29597 3/20 0.42
▸ JAK1 P23458 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ MTOR P42345 1/20 0.41
▸ SMG1 Q96Q15 1/20 0.41
▸ NUAK1 O60285 1/20 0.41
▸ STK16 O75716 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ CSF1R P07333 1/20 0.41
▸ CSNK2A2 P19784 1/20 0.41
▸ AAK1 Q2M2I8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633524 0.90 JAK2 (0.50) EGFRFGFR2TBK1JAK2TYK2
SCHEMBL1632155 0.89 IKBKB (0.46) EGFRMAPK10FGFR2CA12CA1
SCHEMBL13498247 0.87 IKBKB (0.44) EGFRFGFR2CA12CA1CA2
SCHEMBL1634505 0.87 TBK1 (0.55) MAPK10CA12CA1CA2CA9
SCHEMBL1633715 0.87 NTRK1 (0.42) MAPK10FGFR2TBK1TYK2MTOR
SCHEMBL1631354 0.84 TYK2 (0.54) EGFRCA12CA1CA2CA9
SCHEMBL1632740 0.82 CYP11B2 (0.42) EGFRCA12CA1CA2CA9
SCHEMBL1632623 0.80 MAPK10 (0.53) EGFRMAPK10JAK2MTORSMG1
SCHEMBL13498295 0.78 MTOR (0.62) EGFRMAPK10CA12CA1CA2
SCHEMBL1633768 0.78 PTK2 (0.45) MAPK10CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 — — US disclosed
Send feedback